The triple-therapy regimen yielded 90% SVR12 in the overall population, and all patient subgroups attained at least 80% SVR12 rate, including patients with cirrhosis and those with IL28B non-CC genotype.
Triple therapy was well tolerated and enabled most patients (91%) to shorten the duration of therapy to 24 weeks while maintaining a high SVR12 rate of 86% in this subgroup.
Most patients receiving faldaprevir (88%) were able to shorten therapy to 24 weeks total, without compromising sustained virologic response, which was 88% in this subgroup.
Triple therapy was well tolerated and 85% of patients were able to shorten treatment to 24 weeks, of whom 91% achieved SVR12.
Efficacy was similar between the 2 treatment arms, but sofosbuvir/ribavirin demonstrated superior safety and tolerability with shorter therapy compared with peginterferon/ribavirin.
Significantly better rates of SVR12 with both 12 and 16 weeks of therapy compared with historical controls, with better outcomes with 16 weeks of therapy among patients with genotype 3 HCV
Sofosbuvir plus ribavirin is a safe, effective, IFN-free alternative for patients chronically infected with genotype 2/3 HCV who have no other treatment options available.
Among patients who completed 12 weeks of triple therapy, 100% SVR12 rate among patients who continued to receive peginterferon/ribavirin through 24 weeks vs 89% SVR4 rate among patients who stopped all therapy at 12 weeks.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.